Company: INTS
Filing Date: 2025-04-25
Form Type: 424B4
Source: 0001628280-25-020056
Chunk: 50

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-04-25
Form: 424B4
Chunk 50
---
 documents incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated by reference into such documents. You should direct any requests for documents to:

#### 1 Enterprise Drive, Suite 430

#### Shelton, CT 06484-4779
<div align='center'>(203) 221-7381</div>

You may also access these documents, free of charge, on the SEC’s website at www.sec.gov or on our website at https://intensitytherapeutics.com/. The information contained in, or that can be accessed through, our website is not incorporated by reference in, and is not part of, this prospectus or any accompanying prospectus supplement.

In accordance with Rule 412 of the Securities Act, any statement contained in a document incorporated by reference herein shall be deemed modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement.

You should rely only on information contained in, or incorporated by reference into, this prospectus and any prospectus supplement. We have not authorized anyone to provide you with information different from that contained in this prospectus or incorporated by reference into this prospectus. We are not making offers to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such an offer or solicitation.

<div align='center'>34</div>

#### 3,133,333 Shares of Common Stock
<div align='center'>3,133,333 Series B-1 Common Warrants to Purchase Up to 3,133,333 Shares of Common Stock

3,133,333 Series B-2 Common Warrants to Purchase Up to 3,133,333 Shares of Common Stock

6,266,666 Shares of Common Stock Underlying the Series B-1 Common Warrants and Series B-2 Common Warrants</div>

### PROSPECTUS
<div align='center'>Lead Placement Agent</div>

| A.G.P. |

<div align='center'>Co-Placement Agent</div>

| Brookline Capital Markets,            
 a division of Arcadia Securities, LLC |

<div align='center'>April 24, 2025</div>